We checked this claim: is it true that
President Donald Trump and First Lady Melania Trump signed an executive order establishing a women's health division at the National Institutes of Health and creating a White House task force?
Trump officially signed the order alongside Melania Trump on October 19, 2026, establishing both bodies under an administrative mandate while leaving funding dependent on existing agency budgets
Trump orders women's health research overhaul
Executive order creates a dedicated division at the federal medical agency without dedicated funding from Congress
In a nutshell
President Donald Trump signed an executive order championed by First Lady Melania Trump to establish a dedicated Women's Health Division within the National Institutes of Health, targeting conditions such as cardiovascular disease and endometriosis. The directive forms a White House task force to guide executive agencies, though its real-world reach depends on shifting existing agency budgets rather than new congressional spending.
Highlights
- Donald Trump officially issued the executive order on October 19, 2026, alongside Melania Trump in the White House Rose Garden.
- The mandate creates a dedicated Women's Health Division inside the National Institutes of Health, the primary federal biomedical agency.
- Health and Human Services Secretary Robert F. Kennedy Jr. and White House Chief of Staff Susie Wiles will co-chair the White House task force.
- Targeted medical priorities include cardiovascular disease, maternal health, menopause, autoimmune disorders, endometriosis, and polyendocrine metabolic ovary syndrome.
- The directive relies on existing discretionary federal agency budgets rather than dedicated statutory appropriations from Congress.
From the Editor’s Diary
Executive orders can reorder federal research priorities overnight, but sustained scientific discovery depends on whether lawmakers back administrative mandates with dedicated funding.
Who's involved
Donald Trump
47th President of the United States
goal → aims to expand biomedical research through high-profile executive orders ahead of midterm elections
Melania Trump
First Lady of the United States
goal → led and championed the administration's dedicated women's health policy push
Robert F. Kennedy Jr.
Secretary of the Department of Health and Human Services
goal → co-chairs the White House task force and manages the integration of the research division
Susie Wiles
White House Chief of Staff
goal → co-chairs the White House task force to coordinate policy across federal agencies
National Institutes of Health
primary U.S. biomedical research agency
goal → tasked with creating and operating the new women's health research unit
In short
Federal laboratories must now prioritize conditions that disproportionately harm women, but the White House order carries no new taxpayer cash. The mandate shifts internal agency focus toward diseases that have long seen uneven attention, moving federal scientists to reallocate dollars they already control.
The directive makes a formal reshuffling of biomedical research priorities across the Department of Health and Human Services likely to follow.
That shift remains uncertain because the White House ordered broad administrative realignment rather than securing dedicated statutory funding through Congress.
Flagged by: Life & Health Science Barometer · 24 October 2026
How it unfolded
Rose Garden signing launches research shift
President Donald Trump and First Lady Melania Trump held a signing event in the White House Rose Garden to announce an executive order aimed at strengthening federal study of women's diseases. The order marked a formal executive rollout led directly by the First Lady, setting the stage for agency shifts without new legislative funding.
Administrative order mandates task force under existing funds
The directive ordered the Department of Health and Human Services to set up a formal Women's Health Division inside the National Institutes of Health and created a White House task force led by cabinet officials. Healthcare groups and policy analysts noted the focus on specific conditions like autoimmune disorders and maternal care, while cautioning that actual grants depend entirely on existing discretionary funds.
Where things stand
The executive order is in effect, leaving federal health officials to organize the administrative structure and identify internal research grants.
Key unresolved questions include whether Congress will appropriate dedicated funds and when the White House task force will deliver its first recommendations.